3058592-86-9
3058592-86-9
Chemical Structure
Zocilurtatug
Synonym(s): ZL-1310 Antibody
- CAS No.: 3058592-86-9
- Formula:N/A
- Molecular Weight:(145.546 kDa)
SMILES: [Zocilurtatug]
Biological Activity: Zocilurtatug (ZL-1310 Antibody) is a human monoclonal antibody targeting DLL3. Zocilurtatug serves as the targeting antibody component of antibody-drug conjugates (ADCs) and is used in research related to small cell lung cancer and neuroendocrine carcinoma. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zocilurtatug | 99.50% | Zocilurtatug (ZL-1310 Antibody) is a human monoclonal antibody targeting DLL3. Zocilurtatug serves as the targeting antibody component of antibody-drug conjugates (ADCs) and is used in research related to small cell lung cancer and neuroendocrine carcinoma. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. American Association for Cancer Research (AACR). Investigational Antibody-drug Conjugate Shows Clinical Benefit Against Previously Treated Small Cell Lung Cancer. News Release. October 22, 2025.
- [2]. Kemper M, et al. Redefining the Fight Against SCLC: Standards, Innovations, and New Horizons. Cancers (Basel). 2025 Jul 7;17(13):2256. [Content Brief]
